These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 5790046)

  • 1. Phenformin effect on body weight, lipids and glucose regulation.
    Alterman SL
    Pol Arch Med Wewn; 1969; 42(3):291-7. PubMed ID: 5790046
    [No Abstract]   [Full Text] [Related]  

  • 2. Phenformin effect on body weight, lipids, and glucose regulation.
    Alterman SL; Lopez-Gomez AA
    Ann N Y Acad Sci; 1968 Mar; 148(3):884-91. PubMed ID: 4872312
    [No Abstract]   [Full Text] [Related]  

  • 3. Diabetes mellitus and obesity: phenformin hydrochloride as a research tool.
    Danowski TS
    Metabolism; 1967 Sep; 16(9):865-9. PubMed ID: 4860366
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of phenformin hydrochloride on serum cholesterol, triglycerides and body weight of nondiabetic hypercholesterolemic subjects.
    Burstein J; Jakobson T; Lindell KA; Nikiforow RE
    Ann Med Intern Fenn; 1968; 57(1):15-21. PubMed ID: 5726760
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence of hypoglycemic therapy on blood lipids and body weight in diabetes mellitus.
    Mirsky S
    Ann N Y Acad Sci; 1968 Mar; 148(3):937-44. PubMed ID: 4872314
    [No Abstract]   [Full Text] [Related]  

  • 6. Diabetes mellitus and obesity: phenformin hydrochloride as a research tool. Concluding remarks.
    Danowski TS
    Ann N Y Acad Sci; 1968 Mar; 148(3):958-62. PubMed ID: 5241487
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of hypoglycemic agents on blood lipids and body weight in ketoacidosis-resistant diabetics.
    Gershberg H; Javier Z; Hulse M; Hecht A
    Ann N Y Acad Sci; 1968 Mar; 148(3):914-24. PubMed ID: 4968572
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect of phenethylbiguanide on body weight and some serum lipid indices in obese subjects, obese diabetics and obese subjects with potential diabetes].
    Pompei A; Marcenaro A; Foppiani E; Jacopino GE
    Clin Ter; 1969 Dec; 51(6):541-60. PubMed ID: 5371379
    [No Abstract]   [Full Text] [Related]  

  • 9. Phenformin therapy of chemical diabetes.
    Danowski TS; Sunder JH; Stephan T; Nolan S; Ohlsen PM; Ahmad U; Vidalon C; Wingert JP
    J Clin Pharmacol; 1974; 14(11-12):638-50. PubMed ID: 4140199
    [No Abstract]   [Full Text] [Related]  

  • 10. Blood lipids in treated diabetics.
    Perrett AD; Rowe AS; Shahmanesh M; Allison SP; Hartog M
    Diabetologia; 1974 Apr; 10(2):115-8. PubMed ID: 4844186
    [No Abstract]   [Full Text] [Related]  

  • 11. [Changes of the blood lipid pattern in diabetics under treatment with chlorpropamide and phenethyl-1-biguanide].
    Meduri D; Polito R
    Minerva Med; 1969 Jun; 60(49):2439-48. PubMed ID: 5802656
    [No Abstract]   [Full Text] [Related]  

  • 12. [Initial results in the treatment of diabetes mellitus with an association of glibenclamide and phenformin].
    Carta Q; Pugliese F
    Minerva Med; 1974 Jan; 65(1):27-57. PubMed ID: 4214410
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of phenformin hydrochloride on serum cholesterol and triglyceride levels of the stable adult diabetic.
    Schwartz MJ; Mirsky S; Schaefer LE
    Metabolism; 1966 Sep; 15(9):808-22. PubMed ID: 5929037
    [No Abstract]   [Full Text] [Related]  

  • 14. Metabolic abnormalities in premature coronary disease: effects of therapy.
    Tzagournis M; Seidensticker JF; Hamwi GJ
    Ann N Y Acad Sci; 1968 Mar; 148(3):945-57. PubMed ID: 4872315
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of phenformin-HCl on patients with diabetes mellitus, studied under strict balance conditions.
    Geldermans CA; Terpstra J; Krans HM
    Diabetologia; 1975 Oct; 11(5):475-82. PubMed ID: 1181670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oral antidiabetic therapy with delayed-action glibenclamide and phenformin in fixed combination].
    Beringer A
    Minerva Med; 1974 Sep; 65(60):3127-39. PubMed ID: 4214043
    [No Abstract]   [Full Text] [Related]  

  • 17. [The lipid reducing action of phenformin in primary type IV hyperlipoproteinaemia (author's transl)].
    Lang PD; Vollmar J; Klemens UH; von Löwis P; Gries FA; Koschinsky T; Huth K; Pilz E; Schlierf G; Kremer GJ; Lenhart P; Schwandt P; Hammerl H; Studlar M
    Dtsch Med Wochenschr; 1973 Nov; 98(48):2280-6. PubMed ID: 4762828
    [No Abstract]   [Full Text] [Related]  

  • 18. LIMITATIONS IN THE USE OF ORAL HYPOGLYCEMIC AGENTS IN JUVENILE PATIENTS WITH DIABETES.
    KAYE R; DAVIDSON MH
    J Pediatr; 1965 May; 66():844-56. PubMed ID: 14279844
    [No Abstract]   [Full Text] [Related]  

  • 19. [Phenformin treatment of arteriosclerotic patients: changes induced in the plasma lipid picture. Preliminary note].
    Negri AU; Matteoli E; Zaini GF; Riva D
    Minerva Med; 1971 Nov; 62(89):4405-12. PubMed ID: 5162252
    [No Abstract]   [Full Text] [Related]  

  • 20. Variability in blood cholesterol, triglycerides, free fatty acids, glucose and body weight in maturity-onset diabetics.
    Hulse M; Gershberg H
    Am J Med Sci; 1969 Aug; 258(2):114-20. PubMed ID: 5805233
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.